Bolt Biotherapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 6.36 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 12.25M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company offers product candidates and platform technologies, including PRA-216, BDC-4182, a Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; the Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, and the INSPIRE platform. It serves patients, clinical investigators, and biopharmaceutical partners. The company is based in Redwood City, California.
Details
| Name | Bolt Biotherapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 23 |
| Founded | 2015 |
| Ipo Date | 2021-02-05 |
| Ceo | William Quinn |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Ipo Price | 20.00 |
| Isin | US0977022039 |
| Cusip | 097702203 |
| Cik | 1641281 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| William P. Quinn | Chief Executive Officer, Chief Financial Officer, President, Secretary and Director |
| Grant Yonehiro C.F.A., M.B.A. | Chief Operating Officer and Chief Business Officer |
| Sarah Nemec | Senior Vice President of Finance and Principal Accounting Officer |
| Dr. Michael N. Alonso Ph.D. | Senior Vice President of Research |
| Justin Kenkel | Senior Principal Scientist |
Contact
| Address | 900 Chesapeake Drive, Redwood City, California 94063, United States |
| Phone | 650 665 9295 |
| Website | https://www.boltbio.com |